Novavax Inc

NVAXNASDAQ · USD
7.47USD0.00 (-3.24%)
179

Novavax Inc (NVAX) Covered Calls

Novavax Inc trades in the Biotechnology industry with an IV Rank of 31.94%, average versus the past year. NVAX's highest covered call setup is the $30.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 301.61% out of the money with 56 days to expiration, a 301.74% return until expiration, and a 1,966.70% theoretical annualized return. Across the setups shown, annualized returns run from 616.59% to 1,966.70% at strikes between $8.50 and $30.00, with 7 to 147 days to expiration, as of Nov 20, 2026.

Read more

Running NVAX covered calls helps you generate income from Novavax Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best NVAX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If NVAX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling NVAX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given NVAX covered call is worth writing.

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.

2027-01-155630.00301.610.010.082254.00301.741966.70-0.13+0.0318,8120.07
2027-01-155625.00234.670.010.151754.00234.811530.43-0.13+0.051,6500.14
2026-12-182815.00100.800.020.69755.00101.071317.53-0.27+0.19730.67
2026-12-041411.0047.260.010.12354.0047.391235.51-0.13+0.0870.11
2027-01-155620.00167.740.040.071257.00168.271096.78-0.54+0.048,8510.03
2026-11-2778.5013.790.010.09104.0013.92725.95-0.13+0.131240.08
2026-12-112110.5040.560.031.35306.0040.96711.99-0.40+0.3531.32
2027-01-155615.00100.800.050.28758.00101.47661.38-0.67+0.117,3740.23
2026-12-182811.0047.260.050.07358.0047.93624.74-0.67+0.082,2640.02
2027-04-1614726.00248.060.020.391855.00248.33616.59-0.27+0.10890.37

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank31.94% Moderate
  • Market cap (M$)1,233
  • 52 weeks high-44.17%
  • 52 weeks low19.71%
  • Analyst recommendationHold
    2.62
  • Target price$13.88
    85.81% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.47
  • EPS growth next 5 years—

As of Nov 20, 2026